Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 14/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.61 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.60 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.55 |
| ▸ | CLK2 | P49760 | 1/20 | 0.54 |
| ▸ | BLK | P51451 | 1/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.54 |
| ▸ | STK3 | Q13188 | 1/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.54 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.54 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30814808 | 1.00 | TGFBR1 (1.00) | TGFBR1MAPK14ROCK2ROCK1CLK2 | |
| SCHEMBL6704579 | 0.88 | TGFBR1 (0.79) | TGFBR1MAPK14ROCK2 | |
| SCHEMBL18114567 | 0.86 | TGFBR1 (0.76) | TGFBR1MAPK14ROCK2 | |
| SCHEMBL29395013 | 0.83 | TGFBR1 (0.71) | TGFBR1ROCK2ROCK1CLK2BLK | |
| SCHEMBL13154697 | 0.83 | TGFBR1 (0.71) | TGFBR1ROCK2ROCK1CLK2BLK | |
| SCHEMBL3586914 | 0.83 | TGFBR1 (0.71) | TGFBR1ROCK2ROCK1CLK2BLK | |
| SCHEMBL3113958 | 0.83 | TGFBR1 (0.71) | TGFBR1ROCK2ROCK1CLK2BLK | |
| SCHEMBL3585107 | 0.82 | TGFBR1 (0.69) | TGFBR1ROCK2ROCK1CLK2BLK | |
| SCHEMBL22201315 | 0.82 | TGFBR1 (0.70) | TGFBR1ROCK2ROCK1CLK2BLK | |
| SCHEMBL3574349 | 0.82 | TGFBR1 (0.69) | TGFBR1ROCK2ROCK1CLK2BLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180920-A1 | CERTAIN FASCIN BINDING COMPOUNDS FOR SPINOGENESIS | SPINOGENIX INC (US) | 2024-06-06 | — | — | US | disclosed |
| CN-117320713-A | Certain fascin-binding compounds for dendritic spine production | 斯皮诺吉尼克斯公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | ELECTROPHORETICS LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-20140031547-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES | ELECTROPHORETICS LIMITED | 2014-01-30 | — | — | US | disclosed |
| WO-2004065392-A1 | CONDENSED PYRIDINES AND PYRIMIDINES AND THEIR USE AS ALK-5 RECEPTOR LIGANDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180920-A1 | CERTAIN FASCIN BINDING COMPOUNDS FOR SPINOGENESIS | NEFM, FSCN1, STMN1 | TGFBR1 4184/4885MAPK14 1175/4885ROCK2 1171/4885 |
| US-20140031547-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES | CSNK1G1, CSNK1A1, CSNK1G3 | TGFBR1 2376/4885MAPK14 871/4885ROCK2 712/4885 |
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | CSNK1G1, CSNK1A1, CSNK1D | TGFBR1 3476/4885MAPK14 636/4885ROCK2 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.